ANNEXA-1: Andexanet Alfa Associated with Harm in DOAC Reversal
REBEL Cast
00:00
Navigating Medical Research Ethics and Integrity
This chapter explores the transformation in the podcast's approach to evaluating medical literature over the last decade, stressing the significance of critical analysis and fact-checking in health research. It highlights concerns about funding's impact on research integrity and calls for clinicians to uphold ethical standards in their practice.
Transcript
Play full episode
Background: In May of 2018, Andexanet alfa gained accelerated approval by the FDA for the reversal direct oral anticoagulants (DOACs) despite a lack of robust evidence for use. The 2022 AHA/ASA guidelines give the drug a level 2A recommendation and recommend it over the use of 4F-PCC (Greenberg 2022). FDA approval alongside guideline endorsement has ... 
